CD44

Across TCGA pan-cancer cohorts, CD44 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CD44 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CD44 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CD44 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LSCC show a favorable association.

CCRCC, GBM, and PDAC are the cancer types where CD44 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.367	0.774	<.001	39	view →
GBM	DFS	Tertile	All	0.562	0.830	<.001	29	view →
PDAC	DFS	Median	All	0.649	0.906	<.001	29	view →
UCEC	OS	Median	III,IV	1.000	0.433	.007	12	view →
LSCC	DFS	Median	III,IV	1.000	0.580	.003	11	view →
LUAD	OS	Median	All	0.948	0.667	.025	2	view →
HNSC	OS	Median	IV	0.756	0.887	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CD44–CCRCC (DFS)

Open the CCRCC breakdown →